An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia

Trial Profile

An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Tipelukast (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors MediciNova
  • Most Recent Events

    • 14 Apr 2018 Interim analysis results (n=9) in patients who completed 4 weeks of treatment, presented at The International Liver Congress 2018.
    • 13 Apr 2018 Interim results (n=15) presented in a MediciNova Media Release.
    • 01 Apr 2018 Primary endpoint has been met. (To measure the change from baseline at 12 weeks of MN-001 on serum triglyceride levels in NASH subjects with hypertriglyceridemia), according to a MediciNova media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top